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Polyethylene glycol–superoxide dismutase inhibits lipid
peroxidation in hepatic ischemia/reperfusion injury
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and John R Kirkpatrick
Background:  Hepatic injury after ischemia/reperfusion is attributed to the
development of oxygen free radical (OFR)-mediated lipid peroxidation – a
process that can be measured through its byproducts, specifically
malondialdehyde. The use of free radical scavengers can offer significant
protection against OFR-induced liver injury. We hypothesize that a new potent
OFR scavenger, polyethylene glycol–superoxide dismutase (PEG–SOD), can
inhibit OFR-mediated lipid peroxidation in hepatic ischemia/reperfusion injury.
Methods: Twelve male Sprague–Dawley rats (300–350g) were subjected to
occlusion of the left and middle hepatic arteries and portal veins for 90min,
followed by 120min reperfusion. PEG–SOD (5000 units/kg) was given
intravenously before vascular occlusion and again immediately upon reperfusion
to six rats. Normal saline was given to the remaining six rats to be used as a
control group. The right hepatic lobe (used as internal control) and left hepatic
lobe were harvested separately and tissue malondialdehyde was measured.
Results: A marked increase in lipid peroxide was found in the normal saline
group after 2h reperfusion. Treatment with PEG–SOD prevented the rise in
tissue malondialdehyde. The mean difference in the malondialdehyde between
the left and right hepatic lobes were 13.20±6.35 and 1.70±3.65nmol/g in the
normal saline (control) and PEG–SOD groups, respectively. This difference was
found to be statistically significant (P<0.005) using Student’s t-test.
Conclusions: PEG–SOD can effectively attenuate hepatic ischemia/reperfusion
injury by inhibiting OFR-mediated lipid peroxidation.
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Introduction
Total interruption of hepatic blood flow is often necessary
during hepatic surgery. Upon revascularization and reoxy-
genation, the organ undergoes a process termed reperfu-
sion injury that further impairs organ function. One
mechanism of this injury is explained by oxygen free
radical (OFR) damage to cellular membranes, which leads
to the generation of byproducts of lipid peroxidation, such
as malondialdehyde [1–3]. An initial OFR formed from
molecular oxygen, with the aid of the enzyme xanthine
oxidase, is superoxide anion. This can lead to the genera-
tion of other reactive oxygen species, such as hydroxyl
radical and hydrogen peroxide [1,4]. Protection from these
OFRs comes from endogenous scavengers such as super-
oxide dismutase (SOD), glutathione peroxidase, and cata-
lase. These scavengers are rapidly depleted by the high
amount of reactive oxygen agents produced by the re-
entry of oxygenated blood into the ischemic tissue,
however [5]. Restitution of these OFR scavengers can
attenuate the ischemia/reperfusion injury.
The administration of exogenous SOD has been tested in
several experimental models, but the results are still con-
troversial, primarily because of the short half-life of native
SOD (6min) [5–9]. Recently, a longer-acting form of SOD
with a half-life of 14h was developed through its conjuga-
tion to polyethylene glycol (PEG). We hypothesize that
PEG–SOD, a potent superoxide anion scavenger, can
inhibit OFR-mediated lipid peroxidation in hepatic
ischemia/reperfusion injury.
Materials and methods
Preparation of ischemic rats
Twelve male Sprague–Dawley rats (Harlan Sprague
Dawley Inc, Indianapolis, IN, USA) weighing 300–350g
were used. The animals were housed in wire-bottomed
cages and allowed free access to standard laboratory chow
and water. The animals were not fasted overnight and
were allowed to drink water freely.
OFR = oxygen free radical; SOD = superoxide dismutase; PEG = polyethylene glycol.An injection of 50mg/kg pentobarbital sodium (Nembutal
50mg/ml; Abbott Laboratories, North Chicago, Illinois,
USA) was given intraperitoneally for anesthesia. The hair
over the abdomen and neck was clipped for exposure.
Next, the left carotid artery was cannulated with a 20cm
segment of polyethylene tube (Clay Adams, Parsippany,
NJ, USA) and used to administer heparin (200IU/kg body
weight). Attention was then turned to the abdomen where
the hepatic and portal vessels supplying the median and
left lateral hepatic lobes were occluded for 90min with a
loop of 0 silk suture, which was secured with a clamp and a
flanged polyethylene tube.
Before vascular occlusion, six of the animals received a 5000
units/kg bolus of PEG–SOD and the other six received an
equivalent volume of normal saline (control group). Reflow
was achieved by removal of the clamp, polyethylene tube,
and suture. Immediately upon reperfusion, another 5000
units/kg bolus of PEG–SOD was given to the group that
received PEG–SOD earlier and an equivalent volume of
normal saline was given to the control group. Continuous
blood pressure measurements were obtained using the arte-
rial catheter. The systolic blood pressure was noted to be
greater than 90mmHg at all times.
After 120min of reperfusion, the left and right lobes of the
liver were harvested and stored in a refrigerated container
and the animals were decapitated. The liver specimens
were kept in a –80°C freezer overnight for 16h to be ana-
lyzed the following day.
Polyethylene glycol–superoxide dismutase
The preparation was provided by the Sigma–Aldrich Cor-
poration (St Louis, MO, USA). This SOD enzyme is
derived from bovine erythrocytes and coupled to
methoxy-polyethylene glycol through secondary amine
linkage. PEG, when conjugated to protein, shields the
protein from interaction with other macromolecules. This
generally decreases immunogenicity and proteolysis.
The enzyme has an activity of approximately 4000
units/mg protein. This was diluted in normal saline to a
concentration of 4000 units of activity per ml.
Assay of lipid peroxide
The assay of lipid peroxide was performed according to a
modified version of the method of Masugi and Nakamura
[10]. The measurement of liver lipid peroxide by a colori-
metric reaction with thiobarbituric acid is described in
detail below, and the determined lipid peroxide is referred
to as malondialdehyde.
After thawing the frozen liver, 2ml of 0.05mol/l phosphate
buffer (pH7.4) was added to 1g liver. The resulting
mixture was homogenized using a teflon-pestled homoge-
nizer. The homogenate was used for experiments. To
0.5ml liver homogenate in a teflon-stoppered test tube,
2.5ml of 20% trichloroacetic acid solution and 1ml of
0.67% thiobarbituric acid solution were added. The color
of thiobarbituric acid pigment was developed in a water
bath at 100°C for 30min.
After cooling with tap water to room temperature, 4ml
n-butanol was added and shaken vigorously. After cen-
trifugation, the color of butanol layer was measured at
535nm. 1,1,3,3-tetraethoxypropane was used as a standard
of malondialdehyde.
Statistical analysis
Statistical analysis was performed using Student’s t-test.
P<0.05 was considered statistically significant. Results are
presented as mean ±standard deviation.
Results
Evaluation of the degree of lipid peroxidation was deter-
mined by measuring tissue malondialdehyde in nmol/g
wet liver weight. In the control group, which was given
normal saline, the mean malondialdehyde in the left
hepatic lobe increased significantly compared with the
right lobe, with values of 59.95±6.67 and
46.75±2.79nmol/g, respectively. The group that was
given PEG–SOD did not show a statistically significant
difference in malondialdehyde values between the left
and right hepatic lobes, with levels of 47.80±1.68 and
46.10±3.31nmol/g, respectively (Fig. 1).
A more appropriate analysis that incorporates both the
internal and external controls and compares the mean dif-
ference in malondialdehyde between the normal saline
group and the PEG-SOD group may be seen in Table 1.
This showed that the mean difference in malondialde-
hyde between the left and right hepatic lobes in the
control group was significantly higher than that in the
PEG–SOD group, with levels of 13.20±6.35 and
1.70±3.65nmol/g, respectively.
Discussion
Hepatic ischemia is a common event in modern day
surgery. It is evident in transplantation, trauma, and states
of low blood flow or shock. The re-establishment of blood
flow is necessary in rescuing ischemic tissues, because this
permits both the restoration of cell charge and the
washout of toxic metabolites. However, reperfusion of
ischemic tissues also leads to a sequence of events that,
paradoxically, injures tissues.
One proposed mechanism of ischemia/reperfusion injury
is OFR-mediated lipid peroxidation of cellular mem-
branes, a process that can be measured through the gener-
ation of malondialdehyde, a relatively stable intermediate
of lipid peroxidation that has been widely accepted as a
marker of OFR-mediated lipid peroxidation [1,11–13].
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have also been used because of their organ-specific utility
and have been shown to correlate well with malondialde-
hyde levels. A few examples of these markers are transam-
inases for the liver, creatinine for the kidney, and amylase
for the pancreas. In the past, conclusions have been drawn
regarding the effectiveness of antioxidants in attenuating
OFR-mediated ischemia/reperfusion injury solely based
on the theoretical mechanism of injury, mechanism of
drug action, and the diminished levels of organ-specific
markers of injury. Because evidence of oxidant stress is
only implied and not documented, these conclusions
regarding the appropriate and effective use of these drugs
remain in question. The use of malondialdehyde as our
marker of injury allowed us to demonstrate the appropri-
ate and effective role of PEG–SOD in inhibiting OFR-
mediated lipid peroxidation.
Active research continues to clarify the source of OFRs
and its relative contribution to ischemia/reperfusion
injury. Possible sources include hepatocytes, endothelial
cells, Kupffer cells, and activated neutrophils called upon
to repair the injured organ. The use of various drugs,
cytokines, and monoclonal antibodies to suppress the
activity of inflammatory cells has been shown to be effec-
tive in attenuating ischemia/reperfusion injury, especially
if given before the injury [14,15]. Regardless of the precise
source of OFRs, tissue reoxygenation after ischemia leads
to the generation of superoxide anion as an important
initial OFR. Other reactive oxygen intermediates that may
play a role in ischemia/reperfusion injury are hydrogen
peroxide and hydroxyl radical; their production usually
originates from the generation of superoxide anion,
however. In essence, the administration of PEG–SOD can
attenuate ischemia/reperfusion injury by scavenging
superoxide anion and halting the deleterious chain reac-
tion that would lead to the generation of other reactive
oxygen intermediates.
PEG–SOD has other characteristics that would make it an
ideal OFR scavenger. First, SOD is a potent endogenous
superoxide anion scavenger. Second, its binding to PEG
allows it to resist degradation by proteolysis. Third, it is
specific for superoxide anion; therefore, it will not produce
adverse effects from generalized inhibition of inflamma-
tion as seen with corticosteroids or other immunosuppres-
sants. Lastly, there are no currently known specific adverse
effects from the administration of SOD or PEG–SOD.
PEG–SOD has already been tested in experimental
models of ischemia/reperfusion in muscle, brain, and iso-
lated perfused heart, as well as cold ischemia/reperfusion
damage in isolated pig livers. Results showed a reduced
drop in adenosine triphosphate and lipid peroxide produc-
tion, a higher percentage of tissue survival in muscle,
improved immediate kidney and liver function, and a
smaller brain and myocardial infarction volume in
PEG–SOD treated animals than in untreated ones [16–18].
In the present model, the protective effect of PEG–SOD
was evaluated in the setting of ischemia/reperfusion injury
from clamping and unclamping of the vessels to the left
lateral and median hepatic lobes. This hepatic insult has
been extensively studied and is appropriately suited to
evaluate the process of lipid peroxidation because of the
unique features of the liver. Markers of hepatic injury that
have also been evaluated using this model include adeno-
sine triphosphate depletion, transaminase elevation,
increased polymorphonuclear leukocyte infiltration, and
malondialdehyde elevation, all of which correlate appro-
priately [19]. The present, first use of PEG–SOD in this
setting appears to completely inhibit OFR-mediated lipid
peroxidation. Works from other researchers [1,20–23] have
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Figure 1
Effect of polyethylene glycol–superoxide dismutase (PEG–SOD) and
normal saline on lipid peroxidation. Values are presented as means
±standard deviation. *P<0.005 for left lobe versus right lobe in
normal saline group.
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Table 1
Mean difference in malondialdehyde between the left hepatic
lobe and the right hepatic lobe
Normal saline PEG–SOD
Mean difference in 13.20±6.35 1.70±3.65*
MDA (nmol/g liver tissue)
Comparison of the mean difference in malondialdehyde (MDA)
between the left hepatic lobe and the right hepatic lobe in the normal
saline group and polyethylene glycol–superoxide dismutase
(PEG–SOD) group. *P<0.005, versus normal saline.shown that byproducts of lipid peroxidation can function
as chemoattractants for neutrophils. This may explain the
‘late phase’ of ischemia/reperfusion injury. By inhibiting
the production of these byproducts, PEG–SOD may also
attenuate this ‘late phase’ of ischemia/reperfusion injury.
Unpublished data from our laboratory has shown that mal-
ondialdehyde levels rise modestly after an hour of reperfu-
sion, and then briskly to peak after 2h of reperfusion in
saline-treated groups. In the group that received
PEG–SOD, there was no rise in malondialdehyde levels
throughout its reperfusion period. This finding supports
the view that both ‘early and late’ ischemia/reperfusion
injury can be attenuated with PEG–SOD.
In conclusion, the present study shows that PEG–SOD is
an ideal drug to attenuate hepatic ischemia/reperfusion
injury through its action on superoxide anion, which
appears to play a central role in lipid peroxidation. Further
studies are necessary to determine optimal dosage, admin-
istration time, and combination with other anti-inflamma-
tory regimens to obtain the most effective protection from
hepatic ischemia/reperfusion injury, especially in larger
animals. These therapies may provide a better understand-
ing in areas of hepatic surgery, preservation, and rejection.
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